{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:17Z","timestamp":1791486797527,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020921","name":"Indo Soviet Friendship College of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bioorg.2024.107508","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T16:37:08Z","timestamp":1717432628000},"page":"107508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment"],"prefix":"10.1016","volume":"149","author":[{"given":"Rahul","family":"Dubey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Makhija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Asati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107508_b0005","article-title":"Cancer scenario in India with future perspectives","volume":"8","author":"Ali","year":"2011","journal-title":"Cancer Therapy"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107508_b0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107508_b0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1389200219666180918111528","article-title":"Cancer nanotechnology: a new revolution for cancer diagnosis and therapy","volume":"20","author":"Chaturvedi","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bioorg.2024.107508_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100682","article-title":"Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors","volume":"50","author":"Dallavalle","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107508_b0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2024.107508_b0030","doi-asserted-by":"crossref","unstructured":"Adedokun, K. A., Imodoye, S. O., Bello, I. O., & Lanihun, A. A. (2023). Therapeutic potentials of medicinal plants and significance of computational tools in anti-cancer drug discovery. In Phytochemistry, Computational Tools and Databases in Drug Discovery (pp. 393-455). Elsevier. Doi: 10.1016\/B978-0-323-90593-0.00017-4.","DOI":"10.1016\/B978-0-323-90593-0.00017-4"},{"key":"10.1016\/j.bioorg.2024.107508_b0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: The next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107508_b0040","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107508_b0045","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107508_b0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.107508_b0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.apcsb.2022.11.008","article-title":"CDK regulators\u2014Cell cycle progression or apoptosis\u2014Scenarios in normal cells and cancerous cells","volume":"135","author":"D'costa","year":"2023","journal-title":"Adv. Protein Chem. Struct. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107508_b0060","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1530\/ERC-20-0517","article-title":"Novel insights in cell cycle dysregulation during prostate cancer progression","volume":"28","author":"Ben-Salem","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bioorg.2024.107508_b0065","doi-asserted-by":"crossref","unstructured":"Mughal, M. J., Bhadresha, K., & Kwok, H. F. (2023, January). CDK inhibitors from past to present: A new wave of cancer therapy. In Seminars in Cancer Biology (Vol. 88, pp. 106-122). Academic Press. Doi: 10.1016\/j.semcancer.2022.12.006.","DOI":"10.1016\/j.semcancer.2022.12.006"},{"issue":"24","key":"10.1016\/j.bioorg.2024.107508_b0070","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.7150\/jca.48944","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus endocrine therapy vs. endocrine therapy alone for hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"11","author":"Lin","year":"2020","journal-title":"J. Cancer"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107508_b0075","first-page":"1123","article-title":"CDK4-6 inhibitors in breast cancer: current status and future development","volume":"14","author":"Choo","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107508_b0080","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107508_b0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.apsb.2020.05.001","article-title":"Selective inhibition of CDK4\/6: A safe and effective strategy for developing anticancer drugs","volume":"11","author":"Yuan","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107508_b0090","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3390\/ijms20092353","article-title":"Role of cyclin-dependent kinase inhibitors in endometrial cancer","volume":"20","author":"Giannone","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107508_b0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.bioorg.2024.107508_b0100","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107508_b0105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrm3629","article-title":"Control of cell cycle transcription during G1 and S phases","volume":"14","author":"Bertoli","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11\u201312","key":"10.1016\/j.bioorg.2024.107508_b0110","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"issue":"13","key":"10.1016\/j.bioorg.2024.107508_b0115","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","article-title":"Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment","volume":"21","author":"VanArsdale","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107508_b0120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107508_b0125","doi-asserted-by":"crossref","unstructured":"Mir, M. A., & Jan, A. (2023). Introduction to Cell Cycle and Its Regulators. In Therapeutic potential of Cell Cycle Kinases in Breast Cancer (pp. 53-82). Singapore: Springer Nature Singapore. Doi: 10.1007\/978-981-19-8911-7_3.","DOI":"10.1007\/978-981-19-8911-7_3"},{"issue":"01","key":"10.1016\/j.bioorg.2024.107508_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/BS9.0000000000000009","article-title":"Cell cycle regulation and hematologic malignancies","volume":"1","author":"Dai","year":"2019","journal-title":"Blood Sci."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107508_b0135","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2174\/1568026620666200516152756","article-title":"Small molecule CDK inhibitors for the therapeutic management of cancer","volume":"20","author":"Goel","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107508_b0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"19","key":"10.1016\/j.bioorg.2024.107508_b0145","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.3390\/cancers15194835","article-title":"The Evolving Pathways of the Efficacy of and Resistance to CDK4\/6 Inhibitors in Breast Cancer","volume":"15","author":"Gomes","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2024.107508_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2024.107508_b0155","doi-asserted-by":"crossref","unstructured":"Niu, Y., Xu, J., & Sun, T. (2019). Cyclin-dependent kinases 4\/6 inhibitors in breast cancer: current status, resistance, and combination strategies. J. Cancer, 10(22), 5504. Doi: 10.7150%2Fjca.32628.","DOI":"10.7150\/jca.32628"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107508_b0160","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2024.107508_b0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2019.01.003","article-title":"Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats","volume":"1108","author":"Paul","year":"2019","journal-title":"J. Chromatogr. B"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107508_b0170","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1159\/000487578","article-title":"Voruciclib, a potent CDK4\/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells","volume":"45","author":"Gupta","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107508_b0175","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","article-title":"The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group","volume":"58","author":"Seftel","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107508_b0180","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","article-title":"Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial","volume":"20","author":"Tan","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2024.107508_b0185","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2024.107508_b0190","unstructured":"Peter mikochik (2023), Substituted pyrazolo[1,5-a] pyrimidines for modulating CDK9 activity (U.S. Patent No. 11845754 B2) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/024-100-256-857-139\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0195","unstructured":"Noriko yokose (2023), Method for determining sensitivity of cyclin dependent kinase 4\/6 inhibitor (U.S. Patent No. 11639940 B2) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/119-705-999-788-097\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0200","unstructured":"Alexander bondke (2023), Pyrazolo[1,5-a] pyrimidine-5,7 -diamine compounds as CDK inhibitors and their therapeutic use (U.S. Patent No. 11566029 B2) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/051-185-054-154-27X\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0205","unstructured":"D Craig Karr (2023), Combination therapies for the treatment of breast cancer (European Patent No. 3595725 B1) European patent office https:\/\/www.lens.org\/lens\/patent\/163-985-315-615-238\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0210","unstructured":"Noriko yokose (2022), Method and apparatus for determining sensitivity of cyclin dependent kinase 4\/6 inhibitor (European Patent No. 3715850 B1) European patent office https:\/\/www.lens.org\/lens\/patent\/172-853-599-027-199\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0215","unstructured":"Martin Steve Evans (2022), Cdk inhibitors for treating pah (European Patent No. 3804724 B1) European patent office https:\/\/www.lens.org\/lens\/patent\/024-247-144-014-678\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0220","unstructured":"Copeland jay strum (2021), Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4\/6 inhibitors (U.S. Patent No. 11090306 B2) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/129-844-653-647-521\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0225","unstructured":"Alexander bondke (2021), Pyrazolo[1,5-a] pyrimidine-5,7 -diamine compounds as CDK inhibitors and their therapeutic use (U.S. Patent No. 10927119 B2) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/124-715-318-504-299\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0230","unstructured":"X Francis Tavares (2021), Cdk inhibitors (European Patent No.3567042 B1) European patent officehttps:\/\/www.lens.org\/lens\/patent\/045-777-299-456-374\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0235","unstructured":"Shuai zhao (2021), Dual inhibition of CDK and HSP90 destabilize H1F1 alpha and synergistically induces cancer cell death (U.S. Patent No. 10987356 B2) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/016-577-530-012-736\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0240","unstructured":"Alexander bondke (2020), 4- [[(7- Aminopyrazolo[1,5-A] pyrimidin-5-Yl) amino] methyl] piperidin-3-Ol compounds as Cdk inhibitors (U.S. Patent No. 0345736 A1) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/039-412-214-996-445\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0245","unstructured":"Alexander bondke (2020), Pyrazolo [1,5-A] pyrimidine -5,7-Diamine compounds as Cdk inhibitors and their therapeutic use (U.S. Patent No. 0055862 A1) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/047-476-260-182-787\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0250","unstructured":"X Francis Tavares (2020), Cdk inhibitors (U.S patent No.10696682 B1) U.S patent and trademark office https:\/\/www.lens.org\/lens\/patent\/163-915-821-244-886\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0255","unstructured":"Shuai zhao (2020), Dual inhibition of CDK and HSP90 destabilize H1F1 alpha and synergistically induces cancer cell death (U.S. Patent No. 0155554 A1) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/121-390-311-519-795\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0260","unstructured":"Shuai zhao (2020), Dual inhibition of CDK and HSP90 destabilize H1F1 alpha and synergistically induces cancer cell death (U.S. Patent No. 10729692 B2) U.S. Patent and Trademark Office."},{"key":"10.1016\/j.bioorg.2024.107508_b0265","unstructured":"Copeland jay strum (2019), Anti-neoplastic combinations and dosing regimens using CDk4\/6 inhibitor compounds to treat Rb-positive tumors (U.S. Patent No. 0151311 A1) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/121-478-316-952-041\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0270","unstructured":"Copeland jay strum (2019), Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4\/6 inhibitors (U.S. Patent No. 0030034 A1) U.S. Patent and Trademark Office https:\/\/www.lens.org\/lens\/patent\/101-837-438-441-342\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0275","unstructured":"X Francis Tavares (2019), Cdk inhibitors (U.S patent No. 10189849 B2) U.S patent and trademark office https:\/\/www.lens.org\/lens\/patent\/118-391-595-900-171\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0280","unstructured":"X Francis Tavares (2019), Cdk inhibitors (U.S patent No. 0119292 A1) U.S patent and trademark office https:\/\/www.lens.org\/lens\/patent\/115-022-656-213-445\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0285","unstructured":"X Francis Tavares (2019), Cdk inhibitors (European Patent No.3381920 B1) European patent office https:\/\/www.lens.org\/lens\/patent\/024-529-583-242-862\/frontpage?l=en."},{"key":"10.1016\/j.bioorg.2024.107508_b0290","unstructured":"X Francis Tavares (2018), Cdk inhibitors (U.S patent No. 0201618 A1) U.S patent and trademark office https:\/\/www.lens.org\/lens\/patent\/183-726-586-471-829\/frontpage?l=en."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107508_b0295","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2174\/1568026622666220111143949","article-title":"Pyrimidine-fused dinitrogenous penta-heterocycles as a privileged scaffold for anti-cancer drug discovery","volume":"22","author":"Li","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107508_b0300","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1877946813666221021144829","article-title":"A Review on the Synthesis and Pharmacological Activity of Heterocyclic Compounds","volume":"13","author":"Baranwal","year":"2023","journal-title":"Curr. Phys. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107508_b0305","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph17010104","article-title":"Recent Advances in Pyrimidine-Based Drugs","volume":"17","author":"Nammalwar","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2024.107508_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113309","article-title":"Imidazo [1, 2-c] pyrimidin-5 (6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure","volume":"216","author":"Jansa","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2019.06.055","article-title":"Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity","volume":"179","author":"Diao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114875","article-title":"Design, synthesis and anticancer evaluation of selective 2, 4-disubstituted pyrimidine CDK9 inhibitors","volume":"244","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104064","article-title":"Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl) pyrimidin-2-yl) amino)-1H-indole scaffold: Novel potential CDK9 inhibitors","volume":"102","author":"Hu","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107508_b0330","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1021\/acs.jmedchem.9b00189","article-title":"3, 5, 7-Substituted pyrazolo [4, 3-d] pyrimidine inhibitors of cyclin-dependent kinases and their evaluation in lymphoma models","volume":"62","author":"Jorda","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112239","article-title":"Discovery of a novel series of imidazo [1\u2032, 2\u2019: 1, 6] pyrido [2, 3-d] pyrimidin derivatives as potent cyclin-dependent kinase 4\/6 inhibitors","volume":"193","author":"Shi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117158","article-title":"2-Anilino-4-(1-methyl-1H-pyrazol-4-yl) pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation","volume":"80","author":"Fanta","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105646","article-title":"Identification of a promising hit from a new series of pyrazolo [1, 5-a] pyrimidine-based compounds as a potential anticancer agent with potent CDK1 inhibitory and pro-apoptotic properties through a multistep in vitro assessment","volume":"120","author":"Elgiushy","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104053","article-title":"Synthesis, cytotoxicity of some pyrazoles and pyrazolo [1, 5-a] pyrimidines bearing benzothiazole moiety and investigation of their mechanism of action","volume":"102","author":"Husseiny","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105324","article-title":"Development of pteridin-7 (8H)-one analogues as highly potent cyclin-dependent kinase 4\/6 inhibitors: Synthesis, structure-activity relationship, and biological activity","volume":"116","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107508_b0360","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1021\/acs.jmedchem.9b02121","article-title":"Discovery and SARs of 5-Chloro-N 4-phenyl-N 2-(pyridin-2-yl) pyrimidine-2, 4-diamine derivatives as oral available and dual CDK 6 and 9 inhibitors with potent antitumor activity","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113244","article-title":"Structure-based design of highly selective 2, 4, 5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents","volume":"214","author":"Shao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105431","article-title":"Synthesis of a new series of pyrazolo [1, 5-a] pyrimidines as CDK2 inhibitors and anti-leukemia","volume":"117","author":"Almehmadi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2019.01.008","article-title":"Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo [1, 5-a] pyrimidine scaffold with apoptotic activity","volume":"86","author":"Ali","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107508_b0380","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.molstruc.2018.08.104","article-title":"Synthesis of 4, 6-disubstituted pyrazolo [3, 4-d] pyrimidine analogues: cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation","volume":"1176","author":"Cherukupalli","year":"2019","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2024.107508_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105669","article-title":"Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo [4, 3-b] pyridine derivatives as novel dual FLT3\/CDK4 inhibitors","volume":"121","author":"Li","year":"2022","journal-title":"Bioorg. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824004139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824004139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T23:21:40Z","timestamp":1718407300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824004139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":77,"alternative-id":["S0045206824004139"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107508","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107508"}}